Clinical trials: sponsored by Case Comprehensive Cancer Center
Primary Central Nervous System Non-Hodgkin Lymphoma
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma
This phase II trial studies how well yttrium Y 90 ibritumomab tiuxetan and rituximab work in treating patients with recurrent or refractory primary central nervous system non-Hodgkin lymphoma.
- Trial name
- NCT01973062
- Testing
- rituximab, yttrium Y 90 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Case Comprehensive Cancer Center
Kidney Cancer
Radiosurgery in Treating Patients With Kidney Tumors
RATIONALE: Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I/II trial studies the side effects and best dose of giving stereotactic radiosurgery and to see how well…
- Trial name
- NCT00458484
- Testing
- stereotactic radiosurgery, Renal Biopsy, Serum Blood Markers
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Case Comprehensive Cancer Center
Lung Cancer
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00278148
- Testing
- carboplatin, Erlotinib, paclitaxel
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Nathan Pennell, MD, PhD
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
High-Dose Stereotactic Radiation for Prostate Cancer
This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01664130
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center
Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Erlotinib hydrochloride may also make tumor cells more sensitive to radiation therapy.
- Conditions
- Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx
- Trial name
- NCT01192815
- Testing
- erlotinib hydrochloride, intensity-modulated radiation therapy, pharmacogenomic studies
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with newly…
- Trial name
- NCT00509093
- Testing
- imatinib mesylate, gene expression analysis, mutation analysis
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer
This clinical trial studies positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in measuring tumors in patients undergoing clinical imaging or with newly diagnosed breast cancer.
- Trial name
- NCT01892540
- Testing
- positron emission tomography/computed tomography, PET/MRI, Position Device
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Case Comprehensive Cancer Center
Colon Cancer, Head and Neck Cancer
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
This clinical trial studies positron emission tomography (PET)/magnetic resonance imaging (MRI) in patients undergoing PET/computed tomography (CT).
- Conditions
- Colon Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma
- Trial name
- NCT01557881
- Testing
- magnetic resonance imaging with positron emission tomography scanning
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Case Comprehensive Cancer Center
Childhood Cancer
PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer
This pilot clinical trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI) works compared to PET/computed tomography (CT) in diagnosing younger patients with cancer.
- Trial name
- NCT02287636
- Testing
- fludeoxyglucose F 18, positron emission tomography, computed tomography
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Prostatectomy
Intra-operative Assessment of Cavernosal Nerve Stimulus Threshold
Erectile dysfunction persists in approximately 80% of men 1 year after prostatectomy. Various erectile rehabilitation strategies have not provided benefit.
- Trial name
- NCT03150758
- Testing
- 10Hz + 100 micro-seconds, 10Hz + 200 micro-seconds, 7Hz + 100 micro-seconds
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma, Kahler Disease
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
This study will look at the safety and tolerability of the new drug MLN9708 in combination with the existing drugs panobinostat and dexamethasone among patients with relapsed or refractory multiple myeloma.
- Conditions
- Multiple Myeloma, Kahler Disease, Plasma-Cell Myeloma, Myelomatosis
- Trial name
- NCT02057640
- Testing
- Panobinostat, Dexamethasone, MLN9708
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Jason Valent
Barrett Esophagus
Non-endoscopic Brushing of the Esophagus Using a Non-endoscopic Inflatable Balloon of the Esophagus in Screening for Barrett Esophagus
This pilot clinical trial studies non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus in screening for Barrett esophagus, a condition where the lining of the esophagus has changed…
- Trial name
- NCT02451124
- Testing
- non-endoscopic inflatable balloon for the esophagus, Questionnaire Administration, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Cardiac Disease, Dementia
PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
This randomized pilot clinical trial studies how well positron emission tomography (PET)-magnetic resonance imaging (MRI) works compared to standard-of-care PET-computed tomography (CT) in diagnosing patients with cancer, cardiac…
- Conditions
- Cardiac Disease, Dementia, Inflammatory Disease, Fever of Unknown Origin
- Trial name
- NCT02084147
- Testing
- positron emission tomography, computed tomography, magnetic resonance imaging
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Case Comprehensive Cancer Center
Chemotherapeutic Agent Toxicity, Multiple Myeloma
Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
This randomized phase II trial studies glutamine in preventing peripheral neuropathy in patients with multiple myeloma who are receiving bortezomib.
- Conditions
- Chemotherapeutic Agent Toxicity, Multiple Myeloma, Peripheral Neuropathy
- Trial name
- NCT01783522
- Testing
- glutamine, quality-of-life assessment
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Beth Faiman
Prostate Cancer
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00619515
- Testing
- questionnaire administration, implanted fiducial-based imaging, stereotactic radiosurgery
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT01083368
- Testing
- temsirolimus, bevacizumab, polymorphism analysis
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Case Comprehensive Cancer Center
Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT01408043
- Testing
- plerixafor, filgrastim, etoposide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
Glioblastoma, Glioblastoma Multiforme
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
The purpose of this study is to evaluate the safety and efficacy of TRC105 in patients with recurrent or progressive glioblastoma after prior antiangiogenic therapy (including anti-VEGF therapy)
- Trial name
- 105GM201 (NCT01564914)
- Testing
- TRC105, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Kidney Cancer
Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00853021
- Testing
- aldesleukin, bevacizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Jorge A. Garcia, MD
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of silicon phthalocyanine 4 and photodynamic therapy in treating patients with stage IA-IIA cutaneous T-cell non-Hodgkin lymphoma.
- Conditions
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome
- Trial name
- NCT01800838
- Testing
- silicon phthalocyanine 4, photodynamic therapy, pharmacological study
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Kevin Cooper MD